Elevation Oncology, Inc.
ELEV · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $38 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $5 | $19 | $5 | $4 |
| Gross Profit | -$5 | $19 | -$5 | -$4 |
| % Margin | – | 50% | – | – |
| R&D Expenses | $6,876 | $6,647 | $9,388 | $6,551 |
| G&A Expenses | $3,965 | $3,995 | $3,841 | $4,412 |
| SG&A Expenses | $3,965 | $3,995 | $3,841 | $4,408 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$4 |
| Other Operating Expenses | -$5 | $0 | $0 | $0 |
| Operating Expenses | $10,836 | $10,642 | $13,229 | $10,959 |
| Operating Income | -$14,216 | -$10,642 | -$13,229 | -$10,963 |
| % Margin | – | -28,005.3% | – | – |
| Other Income/Exp. Net | $11 | $215 | $360 | $513 |
| Pre-Tax Income | -$14,205 | -$10,427 | -$12,869 | -$10,450 |
| Tax Expense | $6 | $9 | $12 | $11 |
| Net Income | -$14,211 | -$10,436 | -$12,881 | -$10,461 |
| % Margin | – | -27,463.2% | – | – |
| EPS | -0.24 | -0.18 | -0.22 | -0.18 |
| % Growth | -33.3% | 18.2% | -22.2% | – |
| EPS Diluted | -0.24 | -0.18 | -0.22 | -0.18 |
| Weighted Avg Shares Out | 59,174 | 59,122 | 59,109 | 59,018 |
| Weighted Avg Shares Out Dil | 59,174 | 59,122 | 59,109 | 59,018 |
| Supplemental Information | – | – | – | – |
| Interest Income | $933 | $1,173 | $1,357 | $1,507 |
| Interest Expense | $922 | $958 | $997 | $994 |
| Depreciation & Amortization | $5 | $5 | $5 | $4 |
| EBITDA | -$14,216 | -$9,464 | -$13,224 | -$10,959 |
| % Margin | – | -24,905.3% | – | – |